Pentixather

Pentixather is a radiolabeled peptide that can target CXCR4. Pentixather can disrupt the interaction between leukemic cells and the bone marrow microenvironment by targeting the CXCR4/CXCL12 signaling axis, reduce the retention of leukemic cells in the protective bone marrow niche, and thereby enhance the sensitivity of leukemic cells to treatment. Pentixather can be used for the study of acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) [1].

1339959-27-1

12352209

CXCR

GPCR/G Protein; Immunology/Inflammation

Cancer

O=C(NCC(N[C@@H](C(N([C@@H](C(N[C@H]1CCCNC(N)=N)=O)CCCN)C)=O)CC2=CC=C(O)C=C2)=O)[C@H](CC(C=C3)=CC4=C3C=CC=C4)NC1=O

C36H47N9O6

701.82

[1]Rahimian S, et al. CXCR4-targeted theranostics in acute leukemia: disrupting leukemic cell-microenvironment interactions with pentixafor and pentixather. Med Oncol. 2025 Aug 4;42 (9) :402.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-P11451/

Peptides

No Development Reported

CXCR4